drugset / Trial / NCT05276492

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

NCT05276492

Phase 1 Terminated 50 enrolled University of Chicago
RandomizedSequentialOpen-labelTreatment

Summary

Doctors leading this study plan to collect new information about the lowest effective dose of abiraterone acetate in study participants with prostate cancer who are taking abiraterone in combination with prednisone for the first time. The duration of this study will be about 3 months (12 weeks). How long you stay on abiraterone, and at what dose after completion of the 12 weeks of study drug administration, will be up to you and your treating physician.

Timeline

Start
2023-01-24
Primary completion
2024-11-16
Completion
2024-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 500 mg Oral
Background Prednisone Other / unclassified 5 mg Oral